Bridge Medicines Enters Agreement with Weill Cornell Medicine to Develop a Novel Sphingosine 1-Phosphate (S1P) Receptor Modulator
NEW YORK, NEW YORK – March 11, 2019
Bridge Medicines announced today an agreement with Weill Cornell Medicine to develop a novel sphingosine 1-phosphate (S1P) receptor modulator. This small molecule program originated in the laboratory of Timothy Hla, Ph.D. formerly of Weill Cornell Medicine, now Boston Children’s Hospital, and was successfully advanced by the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI).
Bridge Medicines Enters Agreement with Memorial Sloan Kettering to Develop Kidney‐Specific Delivery Platform for the Treatment of Acute Kidney Injury
NEW YORK, NEW YORK – July 23, 2018
Bridge Medicines announced today an agreement with MemorialSloan Kettering (MSK) to develop a platform designed to deliver drugs specifically to the kidney. The first disease target will be acute kidney injury (AKI), a highly prevalent and currently unmet medical need.
Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
NEW YORK, April 3, 2018 – PRNewswire
Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the appointment of Louis M. Renzetti, Ph.D., as Chief Scientific Officer (CSO).
Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development
Project Originated at Rockefeller University and Graduated From Tri-Institutional Therapeutics Discovery Institute
NEW YORK, March 14, 2018 – PRNewswire
Bridge Medicines and the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) announced today the acceptance into Bridge Medicines of its first drug candidate, a small molecule for the treatment of basal cell carcinoma, that originated in the laboratory of Rockefeller University’s Dr. Tarun Kapoor and successfully completed pre-clinical trials at Tri-I TDI.
Bridge Medicines Appoints William J. Polvino, M.D., As Chief Executive Officer
New York, NY – March 27, 2017
Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the appointment of William J. Polvino, M.D., as Chief Executive Officer (CEO). In conjunction, Kathleen Metters, Ph.D., who served as the interim CEO upon the establishment of Bridge Medicines in October 2016, will continue to have an operating role within Bridge Medicines, and will Chair the Scientific Advisory Board.
Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept
The Tri-Institutional Therapeutics Discovery Institute, a partnership between Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda, joins with Deerfield Management and Bay City Capital to create an accelerated path to innovative therapies to treat disease
NEW YORK and OSAKA, JAPAN (Oct. 31, 2016)
Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.